Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 9;6(1):147.
doi: 10.1038/s41392-021-00590-8.

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19

Xuemei He  1 , Manni Wang  1 , Min Wu  2
Affiliations
Comment

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19

Xuemei He et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Immune phenotyping of red-blood-cell-depleted blood samples but preserving all white blood cells and other serum components of patients with COVID19 using scRNA-seq analysis. Antibodies from patients with severe COVID-19 neutralized ISG induction by binding of FcγRIIb to contribute to the damaging effects in the suffered. Blocking the antibodies targeting FcγRIIb restored the induction of ISGs in PBMCs to reduce the severity of disease in dying patients, ushering in an advancement of immune regulation in the most severe disease and indicating potential effective therapeutic approaches
See this image and copyright information in PMC

Comment on

  • Global absence and targeting of protective immune states in severe COVID-19.
    Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, Chew NW, Cleary SJ, Kushnoor D, Reeder GC, Shen A, Tsui J, Hiam-Galvez KJ, Muñoz-Sandoval P, Zhu WS, Lee DS, Sun Y, You R, Magnen M, Rodriguez L, Im KW, Serwas NK, Leligdowicz A, Zamecnik CR, Loudermilk RP, Wilson MR, Ye CJ, Fragiadakis GK, Looney MR, Chan V, Ward A, Carrillo S; UCSF COMET Consortium; Matthay M, Erle DJ, Woodruff PG, Langelier C, Kangelaris K, Hendrickson CM, Calfee C, Rao AA, Krummel MF. Combes AJ, et al. Nature. 2021 Mar;591(7848):124-130. doi: 10.1038/s41586-021-03234-7. Epub 2021 Jan 25. Nature. 2021. PMID: 33494096 Free PMC article.

References

    1. Combes AJ, et al. Global absence and targeting of protective immune states in severe COVID-19. Nature. 2021;591:124–130. doi: 10.1038/s41586-021-03234-7. - DOI - PMC - PubMed
    1. Lin P, Wang M, Wei Y, Kim T, Wei X. Coronavirus in human diseases: Mechanisms and advances in clinical treatment. MedComm. 2020;1:270–301. doi: 10.1002/mco2.26. - DOI - PMC - PubMed
    1. Wilk AJ, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020;26:1070–1076. doi: 10.1038/s41591-020-0944-y. - DOI - PMC - PubMed
    1. Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science370, 6515 (2020). - PMC - PubMed
    1. Dhodapkar KM, et al. Selective blockade of the inhibitory Fcgamma receptor (FcgammaRIIB) in human dendritic cells and monocytes induces a type I interferon response program. J. Exp. Med. 2007;204:1359–1369. doi: 10.1084/jem.20062545. - DOI - PMC - PubMed